

Reference:	FOI.19232.26
Subject:	Biologic medications in Rheumatology
Date of Request:	6 January 2026

Requested:

Could you please provide the numbers of patients treated by the rheumatology department (for any condition) in the last 3 months with the following drugs:

- Abatacept [Orencia]
- Adalimumab [Humira]
- Adalimumab Biosimilars
- Apremilast [Otezla]
- Baricitinib [Olumiant]
- Bimekizumab [Bimzelx]
- Certolizumab [Cimzia]
- Etanercept [Enbrel]
- Etanercept Biosimilars
- Filgotinib [Jyseleca]
- Golimumab [Simponi]
- Guselkumab [Tremfya]
- Infliximab [Remicade]
- Infliximab Biosimilars
- Ixekizumab [Taltz]
- Risankizumab [Skyrizi]
- Rituximab [MabThera]
- Rituximab Biosimilars
- Sarilumab [Kevzara]
- Secukinumab [Cosentyx]
- Tocilizumab [Ro Actemra]
- Tocilizumab Biosimilars
- Tofacitinib [Xeljanz]
- Upadacitinib [Rinvoq]
- Ustekinumab [Stelara]
- Ustekinumab Biosimilar

Response:

Hywel Dda University Health Board (UHB) provides within the table below, the number of patients treated by the Rheumatology Department with the listed biologic medicines, during the period 1 October to 31 December 2025.

Medicine	Number
Abatacept [Orencia]	110
Adalimumab [Humira]	11
Adalimumab Biosimilars	317
Apremilast [Otezla]	25
Baricitinib [Olumiant]	45
Bimekizumab [Bimzelx]	5

Certolizumab [Cimzia]	39
Etanercept [Enbrel]	19
Etanercept Biosimilars	165
Filgotinib [Jyseleca]	16
Golimumab [Simponi]	25
Guselkumab [Tremfya]	0
Infliximab [Remicade]	0
Infliximab Biosimilars	21
Ixekizumab [Taltz]	6
Risankizumab [Skyrizi]	*
Rituximab [MabThera]	*
Rituximab Biosimilars	34
Sarilumab [Kevzara]	9
Secukinumab [Cosentyx]	66
Tocilizumab [Ro Actemra]	81
Tocilizumab Biosimilars	8
Tofacitinib [Xeljanz]	8
Upadacitinib [Rinvoq]	29
Ustekinumab [Stelara]	0
Ustekinumab Biosimilar	10

Where the figures in the table have been replaced with an asterisk (*), the UHB is unable to provide you with the exact number of patients due to the low number of cases (less than 5), as there is a potential risk of identifying individuals if this was disclosed. The UHB is therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000 (FoIA). This information is protected by the Data Protection Act 2018 (DPA)/UK General Data Protection Regulations (UK GDPR), as its disclosure would constitute unfair and unlawful processing and would be contrary to the principles and articles of the UK GDPR. This exemption is absolute and therefore, there is no requirement to apply the public interest test.

In reaching this decision, the DPA and UK GDPR define personal data as data that relates to a living individual who can be identified solely from that data or from that data and other information, which is in the possession of the data controller.